Recent human tumor immunology research has identified several genes coding
immunogenic peptides recognized by CD8 cytotoxic T lymphocytes (CTLs) in me
lanoma tumors. Very recently, CD4 T cell antigenic epitopes were also deter
mined in certain melanoma tumors. The use of these peptides in conjunction
with human immunotherapy could prove to be of great benefit. However, such
peptides in clinically common tumors of epithelial cell origin, such as of
the stomach, colon, lung, etc., have not yet been determined extensively. W
e describe for the first time an HLA-A31 (A*31012)-restricted natural antig
enic peptide recognized by the CD8 CTL TcHST-2 of gastric signet ring cell
carcinoma cell line HST-2. We also identified the HLA-DRB1*08032-restricted
peptide recognized by the CD4 T cell line TcOSC-20 of squamous cell carcin
oma OSC-20 derived from the oral cavity. The antigenic peptide of HST-2, de
signated F4.2, is composed of 10 amino acid residues with two anchor motif
residues necessary for binding to HLA-A31 molecules. The synthetic F4.2 pep
tide enhanced the reactivity of TcHST-2 against HST-2 cells. Furthermore, i
ntroduction of an expression minigene coding F4.2 peptide to HLA-A31(+) cel
ls conferred cytotoxic susceptibility to TcHST-2 on the cells. Some stomach
cancer lines into which the HLA-A31 gene had been introduced, such as MKN2
8-A31-2, were lysed by TcHST-2, suggesting the presence of F4.2 peptide in
at least some HLA-A31(+) stomach cancers. Furthermore, F4.2 peptide induced
an F4.2 peptide-specific CTL response in at least 30-40% of HLA-A31(+) per
ipheral blood lymphocytes from gastric cancer patients, suggesting that F4.
2 peptide could be used as a cancer vaccine for gastric tumors. The natural
antigenic peptide of OSC-20 was also determined using acid extraction and
biochemical separation and by mass spectrometry. Consequently, OSC-20 pepti
de was designated as the 6-1-5 peptide, an HLA-DRB1*08032-restricted 16-mer
peptide with two possible anchor motifs. It has an amino acid sequence ide
ntical to that of human alpha-enolase, suggesting that it was derived from
the processed parental alpha-enolase protein. We are presently attempting t
o determine the genes that code tumor rejection antigens recognized by HLA-
A24- and A26-restricted T cells, including those of pulmonary and pancreati
c carcinomas. The search for these antigenic peptides may lead to the ident
ification of immunogenic peptide antigens that would be suitable for clinic
al use in commonly occurring epithelial cancers.